Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2009

View Archived Issues

Genentech describes novel MEK kinase inhibitors in a recent patent

New norepinephrine, 5-HT and dopamine reuptake inhibitors in development at DOV

Novel triazole derivatives with antibacterial activity disclosed in a recent Polish patent

Recent Asubio patent reports new peptides with antihypertensive properties

Corcept reports additional results from clinical study of Corlux and Risperdal

Bristol-Myers Squibb initiates phase II trial to compare BMS-690514 and erlotinib in NSCLC

Phase III study sponsored by Antisense Pharma will assess the efficacy and safety of AP-12009

Merck & Co. conducting phase IIa study to evaluate the safety and efficacy of MK-8245

Optimer reports results from pivotal phase III prulifloxacin trial

Insulin signaling, a potential target for Alzheimer's disease

Hawaii Biotech presents phase I results for West Nile virus vaccine

Valdoxan approved for the treatment of major depressive episodes in Europe

Winston receives orphan drug designation for novel postherpetic neuralgia patch

Bioject signs agreement with IAVI to supply Biojector 2000 for delivery of HIV vaccine

Broad-spectrum antibodies developed to neutralize avian and human influenza A viruses

Alexion's Soliris receives marketing approval in Australia for PNH

Penwest commences phase Ib A-0001 trial for mitochondrial diseases

Cerimon initiates enrollment into phase III clinical studies of diclofenac sodium patch

IPM receives grants for development of microbicides to prevent HIV infection in women

Roche divulges chemokine CCR2 antagonists in development for cardiovascular disorders

Genedata and Syngenta expand biomarker discovery collaboration

Novartis patents novel PTPase inhibitors with antidiabetic properties

Genfit presents update on BMGFT-01/02 and BMGFT-03 biomarker programs

Sanofi pasteur's intradermal microinjection influenza vaccine approved in E.U.